Tag Archives: TSX VENTURE

GrowPros

Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

LAVAL, Quebec, Feb. 12, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra”) (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. ( “Neptune”) (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.

GrowPros

Tetra Bio-Pharma Announces $8 million Bought Deal Offering

ORLEANS, Ontario, Feb. 8, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF) a global leader in cannabinoid-based drug development and discovery, announced today that it has entered into a bought deal financing agreement to sell 8,000,000 units of the Company (the “Units”) at a price of $1.00 per Unit for gross proceeds of approximately $8.0 million (the “Offering”).

GrowPros

Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug

OTTAWA, Ontario, Feb. 5, 2018 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company’s PPP001 prescription smokable dried cannabis product.

GrowPros

Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis

OTTAWA, Ontario, Jan. 29, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.

GrowPros

Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)

OTTAWA, Ontario, Jan. 16, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

GrowPros

Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary

OTTAWA, Ontario, Jan. 2, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement”) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors”).

GrowPros

Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and its Late Stage ACMPR Application

OTTAWA, Ontario, Dec. 21, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with a private Canadian corporation (the “Purchaser”) and has started a transaction to monetize GrowPros (GrowPros MMP Inc., Tetra’s wholly-owned subsidiary) (the “Potential Transaction”), to allow Tetra to focus its activities on the drug development and its clinical trials of its pharmaceutical business.

GrowPros

Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC

OTTAWA, Ontario, Dec. 13, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics.

GrowPros

Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony

OTTAWA, Ontario, Dec. 6, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, is pleased to announce that Tetra opened the Toronto Stock Exchange (“TSX”) yesterday at a ceremony to recognize the listing and trading of Tetra, which began on August 16th 2017 under the symbol TBP.

GrowPros

Tetra Bio-Pharma’s Business Model and Commercialization Strategy In Line with the Canadian Government’s Proposed Approach to the Regulation of Cannabis

OTTAWA, Ontario, Nov. 22, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government’s Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model, and that the company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets.

GrowPros

Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria

OTTAWA, Ontario Nov. 16, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps(TM), unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).

GrowPros

Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device

OTTAWA, Ontario, Nov. 9, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps(TM) inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps(TM).

GrowPros

Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis

OTTAWA, Ontario, Oct. 26, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.

GrowPros

Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

OTTAWA, Oct. 19, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).

GrowPros

Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

OTTAWA, Ontario, Oct. 18, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR).

GrowPros

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

OTTAWA, Ontario, Oct. 12, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market – Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident.

GrowPros

Tetra Bio-Pharma Selected to Present at Prestigious BIO Investor Forum In San Francisco October 17-18

OTTAWA, Ontario, Oct. 4, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel.

GrowPros

Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market

OTTAWA, Ontario, Sept. 28, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis.

GrowPros

Tetra Bio-Pharma to Engage in Co-Development and Distribution Partnership With Major Healthcare Specialty Distributor

OTTAWA, Ontario, Sept. 20, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.

GrowPros

Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference – BioPharm America

OTTAWA, Ontario, Sept. 8, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.

GrowPros

Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange

OTTAWA, Ontario, Aug. 16, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (” Tetra ” or the ” Company “) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE).

Supreme Updates Board of Directors

Supreme Announces Conditional Approval to List on the TSX.V

TORONTO, Ontario, April 10, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (CSE:SL)(CSE:SL.CN) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (“TSX.V”) to list the Company’s common shares on the TSX.V.

Aphria

Aphria Continues Success Story With TSX Listing

LEAMINGTON, Ontario, March 21, 2017 /Weed Wire/ — Aphria Inc. (“Aphria” or the “Company”) (TSX VENTURE:APH)(OTCQB:APHQF), a Health Canada Licensed Producer of medical cannabis products, today announced that the common shares (the “Common Shares”) of the Company will begin trading on the Toronto Stock Exchange (“TSX”) as of the open of the market on March 22, 2017.

OrganiGram Inventory

Greg Engel Appointed OrganiGram CEO, Denis Arsenault Steps up as Executive Chairman

MONCTON, New Brunswick, March 1, 2017 /Weed Wire/ — Organigram Holdings Inc. (TSX VENTURE:OGI) (OTCQB:OGRMF) (the “Company”) has appointed a medical marijuana, pharmaceutical, and biotechnology industry veteran as its new chief executive officer.

OrganiGram Inventory

Organigram Completes Investigation and Provides Update on Compensation Policy

MONCTON, New Brunswick, Feb. 27, 2017 /Weed Wire/ — Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the “Company”) announces that it has completed the investigation related to a recent contamination issue which resulted in voluntary recalls of medical cannabis products produced by the Company.

OrganiGram Inventory

Organigram Supports Health Canada Auditing Improvements

MONCTON, New Brunswick, Feb. 9. 2017 /Weed Wire/ — Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the “Company” or “Organigram”) is providing this update regarding recent Health Canada announcements, as well as the Company’s product recall announced December 30, 2016 and January 9, 2017.

Aphria

Aphria Receives Conditional Approval to Graduate to the TSX

LEAMINGTON, Ontario, Feb. 6, 2017 /Weed Wire/ — Aphria Inc. (“Aphria” or the “Company”) (TSX VENTURE:APH) (OTCQB:APHQF) is pleased to announce it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to graduate from the TSX Venture Exchange and list its common shares on the TSX.

Canopy Growth

Canopy Growth and Mettrum Announce Respective Shareholder Approvals of the Plan of Arrangement

SMITH FALLS, Ontario, Jan. 27, 2017 /Weed Wire/ — Canopy Growth Corporation (“Canopy Growth”) (TSX:CGC) and Mettrum Health Corp. (“Mettrum”) (TSX VENTURE:MT) (together, the “Companies”) are pleased to announce the successful results of the Special Meetings of Shareholders of Canopy Growth and Mettrum, held in Smiths Falls, Ontario and Toronto, Ontario, respectively, to approve Canopy Growth’s acquisition of Mettrum by way of a plan of arrangement (the “Arrangement”), as previously announced by the Companies on December 1, 2016.

The Canadian Bioceutical Corp

The Canadian Bioceutical Corporation to List on the CSE and Delist from the TSXV

TORONTO, Ontario, Jan. 23, 2017 /Weed Wire/ — The Canadian Bioceutical Corporation (“BCC” or the “Company”) (TSX VENTURE: BCC.V; OTC PINK: CBICF) today announces that it has received conditional approval to list its common shares on the Canadian Stock Exchange (“CSE”), and intends to voluntarily delist its common shares from the TSX Venture Exchange (the “TSXV”).

Aphria

Aphria’s Vision to be Reality – Part IV Expansion Project to Increase Greenhouse Growing Space to 1 Million Square Feet

LEAMINGTON, Ontario, Jan. 16, 2017 /Weed Wire/ — Aphria Inc. (“Aphria” or the “Company”) (TSX VENTURE:APH)(OTCQB:APHQF) is pleased to announce that its Board approved a $137 million capital project, known internally as Part IV expansion.

OrganiGram Inventory

Organigram Acquires Adjacent Property for Infused Products Manufacturing

MONCTON, New Brunswick, Jan. 10, 2017 /Weed Wire/ — Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the “Company”) is pleased to announce it has entered an agreement for the acquisition of additional lands and premises adjacent to its existing property in Moncton, New Brunswick for $600,000 in cash.

OrganiGram Inventory

OrganiGram Announces Voluntary Product Recall

MONCTON, New Brunswick, Dec. 30, 2016 /Weed Wire/ — Licensed medical marijuana producer Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (“Organigram” or the “Company”) is voluntarily recalling certain lots of medical marijuana which were supplied between August and December 2016 due to the detection of amounts of an unapproved pesticide not registered for use on marijuana under the Pest Control Products Act.

Canadian marijuana stocks regain momentum after Christmas

Canadian Marijuana Stocks Regain Momentum After Christmas

In the last few months, the medical marijuana growers have dominated the trading activity on the TSX Venture in terms of dollar volume almost exclusively, belying a persistent interest from investors in Canada and the United States.

Aphria

Aphria Continues Expansion Strategy

LEAMINGTON, Ontarion, Dec. 14, 2016 /Weed Wire/ — Aphria Inc. (“Aphria” or the “Company”) (TSX VENTURE:APH)(OTCQB:APHQF) announced today that the Company entered into a purchase and sale agreement to acquire 200 acres of fully serviced vacant land for $6.24 million located at 521 Mersea Road 8, Leamington, Ontario.

OrganiGram Inventory

Trailer Park Boys Choose OrganiGram as Strategic Partner

MONCTON, New Brunswick, Nov. 23, 2016 /Weed Wire/ — OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (“OrganiGram” or the “Company”) is pleased to announce that it has been chosen as the exclusive Canadian cannabis producer, business partner and brand developer for Nova Scotia-based Trailer Park Boys (“TPB”).

Aphria

Aphria Welcomes Arlene Dickinson to its Board of Directors

LEAMINGTON, Ontario, Oct. 28, 2016 /Weed Wire/ — Aphria Inc. (“Aphria” or the “Company”) (TSX VENTURE:APH)(OTCQB:APHQF) is pleased to announce that Arlene Dickinson was elected as a new director at the Company’s annual general meeting held on October 27, 2016.

OrganiGram Inventory

Organigram Completes Purchase and Expansion Design of Property

MONCTON, New Brunswick, Oct. 11, 2016 /Weed Wire/ — OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the “Company” or “OrganiGram”) is pleased to announce the closing of its previously announced acquisition of the industrial property adjacent to the Company’s existing facility in Moncton, N.B.

Aphria

Aphria Announces Licence Amendment

LEAMINGTON, Ontario, Sept. 26, 2016 /Weed Wire/ — Aphria Inc. (“Aphria” or the “Company”) (TSX VENTURE:APH)(OTCQB:APHQF) announced an amendment to is licence by Health Canada, allowing it to grow up to 3,600 kilograms of dried cannabis and to sell up to 2,800 kilograms of dried cannabis, over the next year.

OrganiGram Inventory

OrganiGram’s License Capacity Increased by Health Canada

MONTON, New Brunswick, Sept. 22, 2016 /Weed Wire/ — OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the “Company” or “OrganiGram”) is pleased to announce that it has successfully amended its Health Canada licensed sales capacity of dried marijuana to 1,200kg per annum.

Mettrum

Mettrum to Sell Non-Core Subsidiary for $7 Million and Enters Three Year Product Supply Agreement

TORONTO, Ontario, Sept. 20, 2016 /Weed Wire/ — Mettrum Health Corp. (“Mettrum” or the “Company”) (TSX VENTURE:MT) is pleased to announce that it has entered into an agreement with Cannabis Care Canada Inc. (“CCC”) to sell to CCC its wholly-owned subsidiary Mettrum (Bennett North) Ltd. Mettrum Health Corp. announced that it has entered into an agreement with Cannabis Care Canada Inc. to sell to CCC its wholly-owned subsidiary Mettrum (Bennett North) Ltd.

Aphria

Aphria Finalizes Licensing Deal With Tokyo Smoke

TORONTO, Ontario, Sept. 19, 2016 /Weed Wire/ — Aphria Inc. (“Aphria”) (TSX VENTURE:APH)(OTCQB:APHQF), in connection with its previously announced licensing deal with Tokyo Smoke, a premium cannabis-oriented lifestyle brand, has issued to Tokyo Smoke 38,759 common shares of Aphria and 200,000 common share purchase warrants exercisable for a period of 5 years at an exercise price of $3.14 per warrant.

Aphria

Aphria to Triple Its Production Space as it Starts Part III Expansion

LEAMINGTON, Ontario, Sept.16,2016 /Weed Wire/ — Aphria Inc. (“Aphria” or the “Company”) (TSX VENTURE:APH) (OTCQB:APHQF) is pleased to announce that its Board of Directors approved a fully funded $24.5 million capital project as the first phase of its Part III expansion.

OrganiGram Inventory

OrganiGram Announces Issuance of Stock Options

MONCTON, New Brunswick, Sept. 2, 2016 /Weed Wire/ — OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (“OrganiGram” or the “Company”) announces that it has issued an aggregate of 835,600 incentive stock options to various directors and officers of the Company at an exercise price of $1.42 per share.

OrganiGram Inventory

OrganiGram Enters Exclusive Partnership for Oils, Extracts and Edibles

MONCTON, New Brunswick, Sept. 1, 2016 /Weed Wire/ — OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the “Company” or “OrganiGram”) is pleased to announce it has entered into an exclusive product development and distribution agreement with TGS International, LLC (“TGS International”).

OrganiGram Inventory

OrganiGram to Purchase Adjoining 10 Acres and 136,000 sq ft Building

MONCTON, New Brunswick /Weed Wire/ — OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the “Company”) is pleased to announce it has entered into a purchase and sale agreement with Commercial Properties Limited to acquire the adjoining property to its current location in Moncton.


Page 1 of 212
Top